Application of syringic acid-(4-hydroxyl-3,5-dimethoxybenzoic acid) in preparation of medicine for preventing and treating rheumatoid arthritis

A technology of dimethoxybenzoic acid and syringic acid, applied in anti-inflammatory agents, non-central analgesics, medical preparations containing active ingredients, etc., to achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2014-07-02
NANTONG REPAIR AIR CHEM BIOENG
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
Despite this, there are no well-developed proteasome compound inhibitors available for the treatment of rheumatoid arthritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of syringic acid-(4-hydroxyl-3,5-dimethoxybenzoic acid) in preparation of medicine for preventing and treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Immunoprotective effects of proteasome-inhibiting compounds in collagen-induced mouse arthritis animal model

[0021] To construct an animal model of collagen-induced arthritis in mice, and to study the therapeutic effect of proteasome-inhibiting compounds on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, weighing 18-22 g, were randomly divided into 6 groups, namely the normal control group, the model control group, and 3 low, middle and high dose groups of the compound (0.4, 0.8, 1.6 mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and placing it in a refrige...

Embodiment 2

[0026] In vivo immunoprotective effect of proteasome inhibiting compounds on adjuvanted rat arthritis animal model

[0027] To construct an animal model of adjuvant arthritis in rats, and to study the therapeutic effect of proteasome-inhibiting compounds on Adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, weighing 140 g-160 g, were randomly divided into 6 groups, which were normal control group, model control group, three dose groups of low, medium and high doses of proteasome inhibitory compounds (0.2, 0.4, 0.8 mg / kg) and Positive drug control group (methotrexate 1 mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10 mg / ml) into the left hindquarters of the rats. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines, and particularly relates to a compound provided with inhibiting proteasome and capable of preventing and treating rheumatoid arthritis. The molecular structure is syringic acid-(4-hydroxyl-3,5-dimethoxybenzoic acid). The syringic acid-(4-hydroxyl-3,5-dimethoxybenzoic acid) has the beneficial effects of being applied to treatment of the rheumatoid arthritis, and having latent new drug development value.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to proteasome inhibiting compounds for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the wrist) as the fi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61P29/00A61P19/02
Inventor 姚炎华朱鹏葛亮刘晓磊奚年英
Owner NANTONG REPAIR AIR CHEM BIOENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap